Journal ArticleOPEN ACCESS

Cytokine storm release syndrome and the prospects for immunotherapy with COVID-19, part 3: The role of GM-CSF

  • Calabrese L
  • Lenfant T
  • Calabrese C
Cleveland Clinic Journal of Medicine (2020)
DOI: 10.3949/ccjm.87a.ccc057
N/ACitations
Citations of this article
35Readers
Mendeley users who have this article in their library.

Abstract

Granulocyte-macrophage colony-stimulating factor (GM-CSF) has been used experimentally in patients with acute respiratory distress syndrome. Recombinant GM-CSF administered by direct inhalation is currently being studied in a cohort of patients with advanced COVID-19.

Cite

CITATION STYLE

APA

Calabrese, L. H., Lenfant, T., & Calabrese, C. (2020). Cytokine storm release syndrome and the prospects for immunotherapy with COVID-19, part 3: The role of GM-CSF. Cleveland Clinic Journal of Medicine. https://doi.org/10.3949/ccjm.87a.ccc057

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free